- Home
- STSS vs ENVB Comparison
STSS vs ENVB Comparison
Compare STSS & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STSS
- ENVB
- Stock Information
- Founded
- STSS 2017
- ENVB 1994
- Country
- STSS United States
- ENVB United States
- Employees
- STSS N/A
- ENVB N/A
- Industry
- STSS Medical/Dental Instruments
- ENVB Biotechnology: Pharmaceutical Preparations
- Sector
- STSS Health Care
- ENVB Health Care
- Exchange
- STSS Nasdaq
- ENVB Nasdaq
- Market Cap
- STSS 3.0M
- ENVB 3.3M
- IPO Year
- STSS 2022
- ENVB N/A
- Fundamental
- Price
- STSS $0.32
- ENVB $1.72
- Analyst Decision
- STSS
- ENVB Strong Buy
- Analyst Count
- STSS 0
- ENVB 1
- Target Price
- STSS N/A
- ENVB $10.00
- AVG Volume (30 Days)
- STSS 2.4M
- ENVB 349.7K
- Earning Date
- STSS 03-31-2025
- ENVB 03-25-2025
- Dividend Yield
- STSS N/A
- ENVB N/A
- EPS Growth
- STSS N/A
- ENVB N/A
- EPS
- STSS N/A
- ENVB N/A
- Revenue
- STSS N/A
- ENVB N/A
- Revenue This Year
- STSS N/A
- ENVB N/A
- Revenue Next Year
- STSS N/A
- ENVB N/A
- P/E Ratio
- STSS N/A
- ENVB N/A
- Revenue Growth
- STSS N/A
- ENVB N/A
- 52 Week Low
- STSS $0.30
- ENVB $1.62
- 52 Week High
- STSS $18.15
- ENVB $657.00
- Technical
- Relative Strength Index (RSI)
- STSS 12.70
- ENVB 16.97
- Support Level
- STSS $0.34
- ENVB $3.88
- Resistance Level
- STSS $0.42
- ENVB $4.83
- Average True Range (ATR)
- STSS 0.13
- ENVB 3.87
- MACD
- STSS -0.15
- ENVB -8.30
- Stochastic Oscillator
- STSS 1.12
- ENVB 0.22
About STSS Sharps Technology Inc.
Sharps Technology Inc is a medical device company. It offers syringes and other safety products. Sharps provensa, Securgard, and Sologard are ultra-low waste smart safety syringes are designed to eliminate potentially infectious and accidental needlestick injuries.
About ENVB Enveric Biosciences Inc.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders. The company's lead program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. Enveric is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, being studied as a treatment of psychiatric disorders.